CTIS2022-503080-15-00进行中（未招募）1 期
TED17644
Kadmon Corporation LLC0 个研究点目标入组 80 人开始时间: 2023年4月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)CTIS2022-502057-33-00Sanofi-Aventis Recherche & Developpement105
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian stimulation with follitropin deltaInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-508149-42-00Ferring Pharmaceuticals A/S200
招募中
1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.Sepsis associated disseminated intravascular coagulationMedDRA version: 22.0Level: PTClassification code: 10013442Term: Disseminated intravascular coagulation Class: 100000004851MedDRA version: 20.0Level: PTClassification code: 10040047Term: Sepsis Class: 100000004862CTIS2022-502866-25-00Bayer AG86
进行中（未招募）
1 期
A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy Adultslcerative ColitisMedDRA version: 20.0Level: PTClassification code: 10009900Term: Colitis ulcerative Class: 100000004856CTIS2023-507354-32-00Pfizer Inc.45
进行中（未招募）
1 期
To Study the Safety and Pharmacokinetics of BLYG8824A in Patients with Locally Advanced or Metastatic Colorectal Cancersocally Advanced or Metastatic Colorectal Cancers (mCRC)MedDRA version: 27.0Level: PTClassification code: 10052358Term: Colorectal cancer metastatic Class: 100000004864CTIS2023-503409-12-00Genentech Inc.58